Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of mRNA-3745 in Glycogen Storage Disease Type 1a
2022-502963-39-00Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jun 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 2, open-label trial of mRNA-3745 in glycogen storage disease type 1a (GSD1a) (2 arms), sponsored by Moderna Inc. Started Jun 2024; status: completed.
02
Drugs
mRNA-3745
03
Conditions
glycogen storage disease type 1a (GSD1a)
Beyond the preview
Go deeper on 2022-502963-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502963-39-00.